Scholarlink

<p>Chronic inflammation and elevated reactive oxygen species (ROS) are pivotal drivers of osteoarthritis (OA), demanding integrated, pathology-adaptive strategies. Here, we develop an injectable, ROS-responsive hydrogel for intra-articular delivery of human adipose tissue–derived extracellular vesicles (AT-EVs) to enable multifaceted OA treatment. Unlike conventional cell-derived MSC-EVs, AT-EVs are tissue-derived and can be isolated directly from lipoaspirate under aseptic operating-room conditions, providing a clinically practical EV source that bypasses prolonged cell expansion and multi-step culture conditioning. Small RNA-seq established their OA therapeutic potential. To facilitate intra-articular retention, the AT-EVs@BA-CS/EGCG hydrogel is formed via dynamic boronate ester crosslinking between phenylboronic acid–grafted chitosan and epigallocatechin-3-gallate (EGCG), achieving triple functionality: (i) injectable self-healing capacity, (ii) ROS-triggered controlled release, and (iii) synergistic ROS scavenging capacity. In vitro, the hydrogel attenuated oxidative stress, protected chondrocytes, restored matrix homeostasis, and suppressed inflammatory macrophage activation. Integrated small RNA profiling, transcriptomics, and phospho-protein validation consistently implicated PI3K/AKT/mTOR pathway modulation as a key mechanism. In a rat OA model, AT-EVs@BA-CS/EGCG mitigated cartilage degeneration, reduced oxidative damage, and dampened inflammatory macrophage signatures. Collectively, this study provides a clinically practical, ROS-adaptive EV–hydrogel platform with translational potential for OA therapy.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ROS-responsive injectable hydrogel enables controlled release of human adipose tissue–derived extracellular vesicles for multifaceted osteoarthritis therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月29日

查看全文
  • Yikai Wang,
  • Le Kang,
  • Kaizhe Chen,
  • Yu Jiang,
  • Yi Zheng,
  • Peng Xu,
  • Chuandong Wang,
  • Wenhui Zhu,
  • Dequn Wu,
  • Kai Liu

摘要

Chronic inflammation and elevated reactive oxygen species (ROS) are pivotal drivers of osteoarthritis (OA), demanding integrated, pathology-adaptive strategies. Here, we develop an injectable, ROS-responsive hydrogel for intra-articular delivery of human adipose tissue–derived extracellular vesicles (AT-EVs) to enable multifaceted OA treatment. Unlike conventional cell-derived MSC-EVs, AT-EVs are tissue-derived and can be isolated directly from lipoaspirate under aseptic operating-room conditions, providing a clinically practical EV source that bypasses prolonged cell expansion and multi-step culture conditioning. Small RNA-seq established their OA therapeutic potential. To facilitate intra-articular retention, the AT-EVs@BA-CS/EGCG hydrogel is formed via dynamic boronate ester crosslinking between phenylboronic acid–grafted chitosan and epigallocatechin-3-gallate (EGCG), achieving triple functionality: (i) injectable self-healing capacity, (ii) ROS-triggered controlled release, and (iii) synergistic ROS scavenging capacity. In vitro, the hydrogel attenuated oxidative stress, protected chondrocytes, restored matrix homeostasis, and suppressed inflammatory macrophage activation. Integrated small RNA profiling, transcriptomics, and phospho-protein validation consistently implicated PI3K/AKT/mTOR pathway modulation as a key mechanism. In a rat OA model, AT-EVs@BA-CS/EGCG mitigated cartilage degeneration, reduced oxidative damage, and dampened inflammatory macrophage signatures. Collectively, this study provides a clinically practical, ROS-adaptive EV–hydrogel platform with translational potential for OA therapy.

Graphical abstract